Isn't the article title a little premature?Arrow haven't fallen yet. We've yet to see Arrow's target statement and an independent valuation. One 16.7% shareholder indicating they're willing to sell, does not a takeover make!
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025